Literature DB >> 28699

The neuropharmacological actions of amoxapine.

E N Greenblatt, A S Lippa, A C Osterberg.   

Abstract

Amoxapine possesses a broad spectrum of psychotropic actions, including antidepressant and neuroleptic effects in animals. Antidepressant activity is characterized by its ability to inhibit tetrabenazine-induced depression, antagonize reserpine-induced hypothermia and enhance yohimbine lethality. Neuroleptic activity is demonstrated by the ability of amoxapine to decrease locomotor activity, induce ptosis and catalepsy, inhibit apomorphine gnawing and amphetamine stereotyped behavior and by characteristic changes in monkey discriminated avoidance behavior. The fact that punished responding in squirrel monkeys was present was present after repeated administration may indicate an anti-anxiety action of this drug. Evidence is offered that the conversion of the tertiary terminal nitrogen to a secondary amine may alter the pharmacologica properties of dibenzoxazepines in a similar way to the for the phenothiazines.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28699

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

Authors:  A Lippa; P Czobor; J Stark; B Beer; E Kostakis; M Gravielle; S Bandyopadhyay; S J Russek; T T Gibbs; D H Farb; P Skolnick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

Review 2.  Amoxapine: a review of its pharmacology and efficacy in depressed states.

Authors:  S G Jue; G W Dawson; R N Brogden
Journal:  Drugs       Date:  1982-07       Impact factor: 9.546

3.  Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients.

Authors:  A G Robertson; R Berry; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Electrophysiological effects of amoxapine in untreated and in amoxapine-pretreated rat atria.

Authors:  C Delgado; J Manzanares; J Tamargo; C Valenzuela
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.